Can intestinal inflammation and barrier dysfunction reduce dietary iron absorption and lead to low ferritin?

The relationship between intestinal health and iron status is governed by a sophisticated interplay of systemic signaling and mucosal integrity. In clinical settings, chronic gut inflammation is a primary driver of iron deficiency, mediated largely by the body's immune response to inflammatory stressors.

Mechanisms of impaired absorption

Intestinal inflammation directly inhibits the absorption of dietary iron through the IL-6/hepcidin/ferroportin axis. When the gut is inflamed, pro-inflammatory cytokines—primarily Interleukin-6 (IL-6)—signal the liver to increase production of hepcidin, the master regulatory hormone of iron homeostasis.

• Ferroportin degradation: Hepcidin binds to and degrades ferroportin, the only known cellular iron exporter located on the basolateral membrane of duodenal enterocytes.
• Iron sequestration: This degradation traps dietary iron within the intestinal cells, preventing its transfer into the bloodstream. These iron-laden cells are eventually shed into the intestinal lumen, resulting in a net loss of iron.
• Transporter downregulation: Localized inflammation can also directly downregulate Divalent Metal Transporter 1 (DMT1), the protein responsible for importing iron from the gut lumen into the enterocytes.

Impact of barrier dysfunction

Intestinal barrier dysfunction, or increased permeability, exacerbates iron malabsorption by facilitating the translocation of microbial products like lipopolysaccharides (LPS).

• TLR4 Activation: LPS enters the systemic circulation and activates Toll-like receptor 4 (TLR4) on immune cells, further stimulating the release of inflammatory cytokines.
• Feedback loop: This creates a self-reinforcing cycle where barrier failure drives systemic inflammation, which in turn sustains high hepcidin levels and continues to block iron absorption.

Chronic inflammation and the ferritin paradox

While ferritin is the standard clinical marker for iron stores, its interpretation is complex in the context of chronic gut inflammation.

• Acute-phase response: Ferritin serves as an acute-phase reactant; its levels can rise significantly during inflammation independently of actual iron stores. In many inflammatory states, ferritin may appear "normal" (e.g., 30–100 ng/mL) despite a functional iron deficiency.
• Absolute deficiency: Chronic gut inflammation often leads to absolute iron deficiency through persistent occult blood loss from mucosal ulcerations and chronic malabsorption. When the rate of iron loss exceeds the body's capacity to sequester iron, total body stores are depleted.
• Clinical thresholds: In the presence of chronic inflammation, a ferritin level below 30 ng/mL is highly specific for absolute iron deficiency, though clinicians often use a higher threshold (up to 100 ng/mL) to diagnose deficiency in patients with inflammatory bowel disease (IBD) or chronic kidney disease.

Bottom line

Intestinal inflammation and barrier dysfunction significantly impair dietary iron absorption via the hepcidin-ferroportin pathway. While inflammation can paradoxically raise ferritin levels as an acute-phase reactant, the chronic blood loss and malabsorption associated with gut pathology frequently lead to absolute iron deficiency and low ferritin. For patients with suspected gut-driven iron issues, managing mucosal inflammation is critical to restoring normal iron transport and systemic levels.